Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Approved by the FDA in 2002
Notoginsenoside R1 (5-20 μM
Smiles: O[C@@H](CO)[C@H]1OC(=O)C(O)=C1O
5-difluoro-4-{[2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]oxy}phenyl)-N1-phenylcyclopropane-1
GN44028 was used at 1-10 µM in vitro and cellular assays
Trastuzumab deruxtecan othenic acid Approved by the FDA inTrastuzumab deruxtecan (DS 8201a) is an anti human epidermal growth factor receptor 2 (HER2) antibody drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti HER2 antibody, an enzymatically cleavable peptide linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2 positive breast cancer and gastric cancer. Product information CAS Number: 1826843 81 5 Molecular Weight: 493. 48 Formula:
US$ 55.00
US$ 125.00
US$ 109.00